CN112638897A - 一种egfr激酶抑制剂及其制备方法和应用 - Google Patents

一种egfr激酶抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN112638897A
CN112638897A CN201980055090.5A CN201980055090A CN112638897A CN 112638897 A CN112638897 A CN 112638897A CN 201980055090 A CN201980055090 A CN 201980055090A CN 112638897 A CN112638897 A CN 112638897A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980055090.5A
Other languages
English (en)
Other versions
CN112638897B (zh
Inventor
罗会兵
李庆
周华勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Medicine Polytron Technologies Inc
Original Assignee
Shanghai Allist Medicine Polytron Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Medicine Polytron Technologies Inc filed Critical Shanghai Allist Medicine Polytron Technologies Inc
Publication of CN112638897A publication Critical patent/CN112638897A/zh
Application granted granted Critical
Publication of CN112638897B publication Critical patent/CN112638897B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

一种式(I)所示的EGFR激酶抑制剂化合物，以及所述激酶抑制剂化合物的盐、制备方法、药物组合物及其在治疗由EGFR介导的疾病特别是癌症方面的应用。
Figure 620628DEST_PATH_IMAGE001

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201980055090.5A 2018-08-22 2019-08-22 一种egfr激酶抑制剂及其制备方法和应用 Active CN112638897B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810958220.3A CN110857292A (zh) 2018-08-22 2018-08-22 一种egfr激酶抑制剂及其制备方法和应用
CN2018109582203 2018-08-22
PCT/CN2019/101969 WO2020038433A1 (zh) 2018-08-22 2019-08-22 一种egfr激酶抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN112638897A true CN112638897A (zh) 2021-04-09
CN112638897B CN112638897B (zh) 2024-03-01

Family

ID=69591975

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810958220.3A Pending CN110857292A (zh) 2018-08-22 2018-08-22 一种egfr激酶抑制剂及其制备方法和应用
CN201980055090.5A Active CN112638897B (zh) 2018-08-22 2019-08-22 一种egfr激酶抑制剂及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810958220.3A Pending CN110857292A (zh) 2018-08-22 2018-08-22 一种egfr激酶抑制剂及其制备方法和应用

Country Status (2)

Country Link
CN (2) CN110857292A (zh)
WO (1) WO2020038433A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101184A1 (en) 2020-11-11 2022-05-19 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
CN116283914A (zh) * 2021-12-01 2023-06-23 上海艾力斯医药科技股份有限公司 一类嘧啶类化合物、其制备方法及应用
WO2023213882A1 (en) 2022-05-04 2023-11-09 Bayer Aktiengesellschaft Irreversible mutegfr inhibitors
WO2024028316A1 (en) 2022-08-02 2024-02-08 Bayer Aktiengesellschaft 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105254615A (zh) * 2014-07-11 2016-01-20 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315259A (zh) * 2014-07-29 2016-02-10 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN106660993A (zh) * 2014-06-12 2017-05-10 上海复尚慧创医药研究有限公司 一类激酶抑制剂
WO2017120429A1 (en) * 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106660993A (zh) * 2014-06-12 2017-05-10 上海复尚慧创医药研究有限公司 一类激酶抑制剂
CN105254615A (zh) * 2014-07-11 2016-01-20 杭州华东医药集团新药研究院有限公司 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315259A (zh) * 2014-07-29 2016-02-10 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
WO2017120429A1 (en) * 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase

Also Published As

Publication number Publication date
CN112638897B (zh) 2024-03-01
WO2020038433A1 (zh) 2020-02-27
CN110857292A (zh) 2020-03-03

Similar Documents

Publication Publication Date Title
KR101883125B1 (ko) 피리딘 아미도피리미딘 유도체, 그의 제조 방법 및 용도
CN109661394B (zh) Fgfr4抑制剂、其制备方法与药学上的应用
CN110036007B (zh) 吡啶化合物
CN112638897A (zh) 一种egfr激酶抑制剂及其制备方法和应用
CN111148745A (zh) Fgfr抑制剂的结晶形式及其制备方法
EP0853616B1 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
WO2022083657A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2020005935A1 (en) Glucose uptake inhibitors
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
CN116283953B (zh) 含噻唑结构的吲哚啉类化合物及其制备方法和应用
CN113366008A (zh) 一种cd73抑制剂，其制备方法和应用
TWI794576B (zh) 一類含氟取代的苯并噻吩類化合物及其藥物組合物及應用
JP6943886B2 (ja) 縮合ピリミジノピペリジン誘導体、ならびにその製造方法および適用
CN115894486B (zh) 一种氢化吡啶并喹唑啉类化合物、组合物及其应用
CN113527215B (zh) 一种喹唑啉类化合物、制备方法及其应用
TWI820414B (zh) 喹唑啉類化合物、製備方法及其應用
WO2022171018A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN110642836B (zh) Egfr抑制剂及其制备和应用
CN115611865A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN112384506A (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN116655636A (zh) 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途
CN114907324A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai, 201318

Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc.

Address before: 201203 5th floor, building 1, 1227 zhangheng road and 1118 HaLei Road, Pudong New Area Free Trade Zone, Shanghai

Applicant before: Shanghai ALLIST medicine Polytron Technologies Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant